SCHEMBL4034136

SCHEMBL4034136

CC(Nc1nc(-c2ccccc2)cs1)c1ccc(CO)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.60
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
ALDH1A1 P00352 4/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
ROCK2 O75116 2/20 0.50
ROCK1 Q13464 2/20 0.50
PHGDH O43175 1/20 0.49
ELOVL1 Q9BW60 1/20 0.47
LMNA P02545 2/20 0.47
GFER P55789 2/20 0.47
GAA P10253 2/20 0.47
ALOX12 P18054 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
STAT3 P40763 1/20 0.46
APP P05067 1/20 0.46
NPC1 O15118 1/20 0.45
STAT1 P42224 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11385164 0.87 MEN1 (0.70) MAPTMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL4038203 0.80 MAPT (0.62) MAPTMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL4038366 0.79 MAPT (0.53) MAPTMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL4029424 0.78 APP (0.54) MAPTMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL1745407 0.76 MEN1 (0.60) MAPTMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL11499092 0.74 NPC1 (0.64) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL7040902 0.72 MAPT (0.59) MAPTMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL7038389 0.71 MAPT (0.59) MAPTMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL1745328 0.71 MAPT (0.62) MAPTMEN1KMT2AALDH1A1ELOVL1
SCHEMBL29276746 0.71 LMNA (0.58) MAPTMEN1KMT2AROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1357115-B1 ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2009-06-17 EP disclosed
US-7238716-B2 Alkanoic acid derivatives process for their production and use thereof TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) 2007-07-03 US disclosed
US-20040058965-A1 Alkanoic acid derivatives process for their production and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-25 US disclosed
EP-1357115-A1 ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058965-A1 Alkanoic acid derivatives process for their production and use thereof GPR119, ACOX1, ALK MAPT 4719/4885MEN1 3721/4885KMT2A 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.